Cancer biopharma company Kura hires former Amgen lawyer to be CLO
Clinical stage biopharmaceutical company Kura Oncology, Inc. which is developing precision medicines for the treatment of cancer, announced that it has hired James Basta as chief legal officer. He’ll also be the company’s chief compliance officer.
Basta has more than 20 years of combined in-house corporate and law firm experience, said Kura. Most recently, he served as chief corporation counsel at Biogen, where he managed the legal representation for Biogen’s securities filings, board of directors, business development, finance and tax, corporate affairs, employment and information technology. Before joining Biogen in 2006, he was a partner in the corporate and securities practice group at Baker & McKenzie. Mr. Basta earned his J.D. from Northwestern University School of Law and his B.A. in Economics from Northwestern University.
“We are privileged to have an executive of Jim’s caliber join our senior leadership team,” said Troy Wilson, president and CEO of Kura Oncology. “Jim brings more than two decades of experience providing legal guidance and leadership to companies. His deep background in biotechnology, coupled with his expertise in securities, mergers and acquisitions, intellectual property licensing and healthcare compliance, make him well-suited for this role as we work to maximize the value of our pipeline of wholly owned, clinical-stage oncology assets.”